Audit: QRS - DHEA for Health & Longevity
Audit conducted on 09/09/2026 05:00 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER; all content traces to ER text (e.g. action_3_value “DHEA-S first” is supported by ER Risk Mitigation “DHEA-S is measured first”). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER uses no “not formally studied”/”None documented” phrasing; conflict markers and net readings are carried by the tier structure as the checklist prescribes. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No claim strengthened or softened; contraindications keep absolute framing, interactions keep caution framing. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | ER contraindication bullet (anti-estrogens, “Absolute contraindication”) sits in Contraindications; all “Caution/Monitor” bullets sit in Key Interactions. No modifying factors surfaced as risks. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT ids, study names, expert names or brand names anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced; EndoCeutics/Life Extension funding attributions from the ER are omitted rather than reassigned. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-first register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven; tiering and targets give the reader a usable decision frame. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and reference ranges rather than instructing a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative clinical instructions; content is stated descriptively. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise” or “you should” constructions. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; retained acronyms (DHEA-S, HDL, PSA, CYP3A4) are decision-relevant identifiers used verbatim by the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every field is a compressed phrase; rationales, citations and effect sizes are stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by search: no you/your/we/our in the rendered text. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a proactive reader who will test DHEA-S, track eight biomarkers and titrate. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol and monitoring cadence presuppose willingness to run repeat lab panels. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at a general audience; assumes lab access and biomarker literacy. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting mirrors the ER: replacement and intravaginal use rated high, general longevity use rated low. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; only “anti-doping”, which is the ER’s own term. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout; At-A-Glance plain-language wording is ER-verbatim and required by 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Diff against [qrs_template] confirms all fixed headings, gate headings, tier labels and Monitoring column headers are byte-identical. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff of data-qrs-var names against the template: identical set, with the repeatable marker_#/qualitative_item_# rows expanded to 1-8 and 1-7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Full-file diff against the template shows changes only inside variable spans, plus the display:none on risks_medium mandated by 13.5. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped to the QRS is empty; the ER contains no “None documented in human trials to date” or “Not formally studied” phrasing to carry over. The empty Medium risk tier is governed by 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels (“Standard replacement dose”, “Best time of day”, “Baseline biomarkers that drive the protocol”) and all eight Monitoring row labels are the ER’s bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label paraphrased or invented; the Time to Effect labels are lifted from the ER’s “Time to effect” sentence. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan finds no emoji; the ER’s tier emoji are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every field is condensed to a phrase and all rationales/citations stripped; the remaining volume (8 contraindications, 8 interactions, 8 markers, 7 qualitative items) is mandated by 8.2, 9.2, 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment is the first element after <!doctype html> (lines 2-14), before <html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opened and closed by bare “—” lines; the comment’s title text precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Wrapped in an HTML comment and not duplicated by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: “00:03” is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: dhea_2026-0909-0001_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 matches the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0909-0444, in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: dhea_2026-0909-0001_Opus_QRS.html matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | No stray whitespace or unnecessary quoting in any frontmatter value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “DHEA for Health & Longevity”, the ER canonical_topic entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date is 09/09/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0909-0444. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is “Opus 5”, equal to qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block is byte-identical to the template apart from the three variable spans; no badge, AKA line or audit stamp. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion into where DHEA works, where it fails, and its drawbacks. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | All five facts map to distinct Conclusion passages (adrenal decline, adrenal failure, vaginal tissue, failed capsule trials, drawbacks). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “adrenal glands” is rendered as “the glands above the kidneys” and HDL as “protective cholesterol”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items derive from the ER Key Interactions & Contraindications section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Carries the ER’s absolute contraindication (anti-estrogens) plus all seven entries of the ER’s “Populations who should avoid DHEA” list. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationale clauses stripped (e.g. “given repeated reports of activation and mania” reduced to “Bipolar disorder”); no trailing dash clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and classes preserved: PSA above 4 ng/mL, IPSS above 19, Child-Pugh Class C, “prohibited at all times”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify populations that should avoid DHEA. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items derive from the ER Key Interactions & Contraindications section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Covers all eight ER interaction bullets and correctly excludes the anti-estrogen bullet already listed as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale and mitigations dropped; the ER’s em-dash constructions converted to parenthetical drug lists. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs preserved for every class (warfarin/apixaban/clopidogrel/aspirin, glipizide/glimepiride, prednisone/hydrocortisone/dexamethasone, ketoconazole/ritonavir/clarithromycin/grapefruit juice, cimetidine/ibuprofen/naproxen, soy isoflavones, pregnenolone/7-keto-DHEA/Tribulus/boron, resistance training/sauna). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify interactions that change how DHEA is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets come from the ER Therapeutic Protocol section. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and the baseline biomarkers that set the dose are the three decision-bearing aspects of that section. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; action_1_sub and action_3_sub are near-verbatim ER text. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Mood, sexual function & skin, and bone density are exactly the three aspects named in the ER’s “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Mood maps to the High-tier benefit “Reduced Depressive Symptoms” and is placed first; the two remaining aspects both map to Low-tier benefits. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields populated from the ER; the windows 4-8 weeks, 3-6 months and 12 months are the ER’s own. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items map to headings in the ER Expected Benefits section. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a phrase; no effect sizes, citations or mechanisms. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried through; the ER’s “Conflicted” markers and magnitudes are dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items map to headings in the ER Potential Risks & Side Effects section. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a phrase; no frequencies, effect sizes or mechanisms. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The “(HDL)” parenthetical in the ER heading is stripped and the term spelled out. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER’s Medium risk tier holds no items, and risks_medium carries style=”display: none” rather than empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence come from the ER Monitoring Protocol & Defining Success section. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarker rows present (DHEA-S, total and free testosterone, estradiol, HDL cholesterol, fasting glucose and HbA1c, PSA, ALT and AST, hematocrit) with targets and rationale verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence reproduces the ER cadence sentence, including the annual PSA in men. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER’s qualitative-marker list in the Monitoring section. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers are listed in ER order. |
Issues 09/09/2026 05:00
Pass rate 100.00%. No issues found.
Issues 09/09/2026 04:53
- 11.4 — Time-to-effect sub carries no timing: [time_2_sub] (line 519) states “Libido and sexual satisfaction is the endpoint with the most consistent trial support”, which explains nothing about the “3–6 months” value above it, duplicates qualitative_item_4’s ER source, and contains a subject-verb agreement error.
Fixes 09/09/2026 04:53
- 11.4 — Time-to-effect sub carries no timing: Replaced [time_2_sub] with “Sexual-function and skin changes emerge together in this window; libido has the most consistent trial support.” — this anchors the cell to the ER’s “sexual-function and skin changes at 3–6 months” statement and resolves the subject-verb agreement error.